Astrazeneca (AZN) FCF Payout Ratio Growth (3y) (2012 - 2026)
Astrazeneca (AZN) FCF Payout Ratio Growth (3y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Cover Growth (3y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
-18.69% |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
20.26% |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
9.35% |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
21.32% |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
-49.49% |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
-16.50% |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
-10.25% |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
-67.11% |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
- |
| 10 |
Biogen |
30.87 Bn |
26.59 Bn |
1.82 Bn |
- |
| Date | Value |
|---|
| Mar 31, 2026 |
21.32% |
| Mar 31, 2025 |
16.84% |
| Dec 31, 2024 |
28.61% |
| Sep 30, 2024 |
10.85% |
| Mar 31, 2024 |
13.46% |
| Mar 31, 2022 |
-47.18% |
| Sep 30, 2021 |
-3.47% |
| Mar 31, 2019 |
48.36% |
| Sep 30, 2018 |
-17.16% |
| Mar 31, 2016 |
23.48% |
| Dec 31, 2015 |
-81.98% |
| Sep 30, 2015 |
25.06% |
| Mar 31, 2015 |
9.53% |
| Dec 31, 2014 |
-16.46% |
| Sep 30, 2014 |
5.08% |
| Mar 31, 2014 |
51.08% |
| Dec 31, 2013 |
-13.32% |
| Sep 30, 2013 |
-13.58% |
| Mar 31, 2013 |
-7.25% |
| Dec 31, 2012 |
-20.14% |
